An interventional study of TetraGraph (TM) NMT Monitor in Surgery, sponsored by Joseph D. Tobias. Completed at 1 site in United States. Open to participants aged 1 Month to 12 Months. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Joseph D. Tobias · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of train-of-four (TOF) monitoring using the TetraGraph Neuromuscular Transmission Monitor in pediatric patients less than 1 year of age.
Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
Device: TetraGraph (TM) NMT Monitor
TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
TOFr (%)
The Train of Four ratio (TOFr) is a quantitative measure used in anesthesia to assess the depth of neuromuscular blockade and recovery, calculated by dividing the amplitude of the fourth twitch by the first twitch after four 2-Hz stimuli. A TOF ratio is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents. A TOF ratio \>/= 90% is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents.
Time frame: During the surgery (1-3 hrs. avg.)
Amplitude
The amplitude of the muscle action potential in response to electrical stimulation of its corresponding peripheral nerve.
Time frame: During the surgery (1-3 hrs. avg.)
Rate of Muscle Recovery
The amount of time from administration of neuromuscular blockade reversal agent to muscle recovery (TOFr \>/= 90).
Time frame: Baseline, After reversal of neuromuscular blockade during surgery (avg of 1-3 hrs)
| Milestone | TetraGraph (TM) NMT Monitor |
|---|---|
| Started | 50 |
| Completed | 49 |
| Not completed | 1 |
| Withdrew: Patient didn't receive neuromuscular blocking agent | 1 |
The Train of Four ratio (TOFr) is a quantitative measure used in anesthesia to assess the depth of neuromuscular blockade and recovery, calculated by dividing the amplitude of the fourth twitch by the first twitch after four 2-Hz stimuli. A TOF ratio is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents. A TOF ratio \>/= 90% is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents.
| percent | TetraGraph (TM) NMT Monitor |
|---|---|
| Baseline | 99 ± 16.3 |
| Recovered (after reversal of neuromuscular blockade) | 95 ± 10 |
The amplitude of the muscle action potential in response to electrical stimulation of its corresponding peripheral nerve.
| millivolts | TetraGraph (TM) NMT Monitor |
|---|---|
| Baseline | 6.8 ± 2.2 |
| Recovered | 4.7 ± 1.5 |
The amount of time from administration of neuromuscular blockade reversal agent to muscle recovery (TOFr \>/= 90).
| minutes | TetraGraph (TM) NMT Monitor |
|---|---|
| Rate of Muscle Recovery | 2.7 ± 1.4 |
Collected over Day of surgery, 1 day. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TetraGraph (TM) NMT Monitor | 0/49 (0%) | 0/49 (0%) | 0/49 (0%) |
| Age, Continuous(months) | TetraGraph (TM) NMT Monitor |
|---|---|
| Mean | 5.45 ± 2.67 |
| Sex: Female, Male(Participants) | TetraGraph (TM) NMT Monitor |
|---|---|
| Female | 21 |
| Male | 28 |
| Ethnicity (NIH/OMB)(Participants) | TetraGraph (TM) NMT Monitor |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 44 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | TetraGraph (TM) NMT Monitor |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 34 |
| More than one race | 10 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | TetraGraph (TM) NMT Monitor |
|---|---|
| United States | 49 |
| Weight(kilograms) | TetraGraph (TM) NMT Monitor |
|---|---|
| Mean | 3.1 ± 1.83 |
| Participants per weight group(Participants) | TetraGraph (TM) NMT Monitor |
|---|---|
| 0 to <4 kg | 3 |
| 4 to <6 kg | 20 |
| 6 to <8 kg | 16 |
| More than 8 kg | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2024 to primary completion in Sep 2024, 2 months.
Results were first posted in May 2026, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joseph D. Tobias